Vimarsana
Biggest News Aggregation in the World

Page 6 - Refractory Multiple News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Refractory Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Refractory Multiple Today - Breaking & Trending Today

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma - Vimarsana News

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

Published: June 3, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of...

Source: prnewswire.com
Related Topics:
United StatesChristie CorbettArnob BanerjeeYael CohenSatu GlaweEarly Development OncologyCompanies Of JohnsonJanssen Pharmaceutical Companies Of JohnsonNational Comprehensive Cancer NetworkNone Of The Janssen Pharmaceutical CompaniesAmerican Society Of Clinical OncologyJanssen Biotech IncNational Cancer InstituteAmerican Cancer SocietyJanssen Research DevelopmentExchange CommissionOther Administration ReactionsAviv Sourasky Medical CenterJanssen Pharmaceutical CompaniesEuropean CommissionHematology InstituteEuropean Medicines AgencyClinical OncologyAnnual MeetingMyeloma Unit
Janssen Presents First Results from Dual Bispecific - Vimarsana News

Janssen Presents First Results from Dual Bispecific

Published: June 3, 2023

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from...

Source: globenewswire.com
Related Topics:
United StatesRegion FlamandeEdmond ChanYael CohenArnob BanerjeeCompanies Of JohnsonCommittee For Medicinal Products Human UseJanssen Research DevelopmentHematology Institute TelEarly Development OncologyAviv Sourasky Medical CenterAmerican Society Of Clinical OncologyJanssen Pharmaceutical Companies Of JohnsonEuropean Medicines AgencyAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesExchange CommissionEuropean CommissionJanssen Pharmaceutical CompaniesClinical OncologyAnnual MeetingMyeloma UnitConfidence IntervalNot EstimableSenior Director
Janssen Presents Longer-Term Talquetamab Follow-Up Data - Vimarsana News

Janssen Presents Longer-Term Talquetamab Follow-Up Data

Published: June 3, 2023

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination...

Source: globenewswire.com
Related Topics:
United StatesCastillay LeópRegion FlamandeTalquetamab MonotherapyMaria Victoria MateosEdmond ChanChris HeuckJanssen Pharmaceutical Companies Of JohnsonNone Of The Janssen Pharmaceutical CompaniesAmerican Society Of Clinical OncologyEuropean Commission Grants Marketing AuthorisationCompanies Of JohnsonAmerican Cancer SocietyEuropean Medicines AgencyExchange CommissionUniversity Hospital Of SalamancaEastern Cooperative Oncology GroupJanssen Biotech IncReceptor Familyc GroupJanssen Research DevelopmentAmerican Society Of HematologyJanssen Pharmaceutical CompaniesClinical OncologyAnnual MeetingSenior Director
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma - Vimarsana News

Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma

Published: June 3, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the...

Source: prnewswire.com
Related Topics:
United StatesTalquetamab MonotherapySatu GlaweBhagirathbhai DholariaChristie CorbettChris HeuckMyeloma CenterCompanies Of JohnsonExchange CommissionJanssen Research DevelopmentOncology At Vanderbilt University Medical CenterReceptor Familyc GroupNone Of The Janssen Pharmaceutical CompaniesDivision Of HematologyEuropean CommissionJanssen Biotech IncNational Comprehensive Cancer NetworkAmerican Society Of Clinical OncologyAmerican Society Of HematologyUniversity Of ArkansasJanssen Pharmaceutical Companies Of JohnsonEastern Cooperative Oncology GroupJanssen Pharmaceutical CompaniesClinical OncologyCarolina Schinke
Legend Biotech Corporation: Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI (ciltacabtagene autoleucel) - Vimarsana News

Legend Biotech Corporation: Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI (ciltacabtagene autoleucel)

Published: May 25, 2023

The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed

Source: finanznachrichten.de
Related Topics:
United StatesNew JerseyGewinn NurYing HuangHemophagocytic LymphohistiocytosisJoanne ChoiTina CarterMedicinal Devices AgencyAmerican Society Of Clinical OncologyJapan Ministry Of HealthLegend Biotech CorporationEuropean Hematology AssociationJanssen Biotech IncJanssen Cilag InternationalEuropean Commission For The Treatment Of PatientsExchange Commission OnCommunity Register Of Orphan Medicinal ProductsAmerican Cancer SocietyEuropean Medicines AgencyDrug AdministrationCorporate CommunicationsEuropean CommissionBiotech CorporationLegend BiotechJanssen Biotech